MBXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MBX Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$52.48+2.87 (+5.79%)
Close on Oct 19, 2026
- Market cap
- $2.50B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
MBX Biosciences has not reported a dividend
No dividend per share appears in MBX Biosciences's annual filings since fiscal 2022.